Tetrandrine tablets for connective tissue disease-related lung disease
Part of Lungs & breathing, Skin clinical trials.
This study tests if tetrandrine tablets can help people with lung disease caused by connective tissue disorders. It is for adults 18-80 who have stable treatment and meet specific health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have lung fibrosis related to a connective tissue disease (like scleroderma or lupus).
- Your lung function test (FVC) must be at least 40% of normal.
- You must not have taken tetrandrine or similar anti-scarring drugs in the past month.
- You must not have active tuberculosis, severe liver or kidney problems, or high blood sugar.
- If you are able to have children, you must use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
This trial tests an inhaled medication called ICF004 in healthy adults to see if it is safe and how the body processes it. It may help in developing a new treatment for lung conditions.
This trial tests a new drug called telitacicept for people with lung scarring caused by connective tissue diseases. It aims to see if the drug can improve lung function and slow down the disease progression.
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
Hear when a new Interstitial Lung Disease (ILD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.